Physician profile
Bradley D Yost
NPI 1073601464
$5,737.94
in general payments reported to CMS, 2019-2025
38 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,920 · 2020: $231 · 2021: $231 · 2022: $1,011 · 2023: $834 · 2024: $912 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.81 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $782.38 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $505.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $438.23 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $327.01 | 2019-2025 | |
| Amgen INC. | $315.54 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $240.14 | 2022-2025 | |
| Glaxosmithkline, LLC. | $234.08 | 2019-2023 | Arexvy, Shingrix |
| Abbott Laboratories | $211.74 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.76 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $160.13 | 2019-2021 | |
| Antares Pharma, INC. | $135.50 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Allergan, INC. | $134.85 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $131.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.02 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Yost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.